Medical Oncology Department.
Hospital General Universitario de Valencia, Valencia, Spain.
Melanoma Res. 2021 Feb 1;31(1):88-91. doi: 10.1097/CMR.0000000000000710.
Nowadays, anti-programmed death-1 (PD-1) antibodies are the first-line treatment for metastatic malignant melanoma. An infusion reaction is an adverse event that could occur due to monoclonal antibodies administration and requires prompt diagnosis and treatment. In this article, we report on a case of stage IV malignant melanoma treated with nivolumab, in which a severe infusion reaction occurred, manifesting as flushing and hypotension followed by bronchospasm. The switch to pembrolizumab was both a well-tolerated and effective therapeutic alternative.
如今，抗程序性死亡-1（PD-1）抗体是转移性恶性黑色素瘤的一线治疗药物。输注反应是由于单克隆抗体给药而可能发生的不良反应，需要及时诊断和治疗。本文报告了一例使用nivolumab 治疗的 IV 期恶性黑色素瘤病例，该患者发生了严重的输注反应，表现为潮红和低血压，随后出现支气管痉挛。改用 pembrolizumab 是一种耐受良好且有效的治疗选择。
